{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:29Z","timestamp":1789383989878,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00458-3","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:12:22Z","timestamp":1785247942000},"page":"1077-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05514132","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuping","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kmieciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"458_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"458_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1296341","volume":"14","author":"A Parvez","year":"2023","unstructured":"Parvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol. 2023;14:1296341. https:\/\/doi.org\/10.3389\/fimmu.2023.1296341.","journal-title":"Front Immunol"},{"issue":"5","key":"458_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006555","volume":"11","author":"T Zhang","year":"2023","unstructured":"Zhang T, Forde PM, Sullivan RJ, et al. Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. J Immunother Cancer. 2023;11(5):e006555. https:\/\/doi.org\/10.1136\/jitc-2022-006555.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"458_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0733-6","volume":"12","author":"L Mei","year":"2019","unstructured":"Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019;12(1):43. https:\/\/doi.org\/10.1186\/s13045-019-0733-6.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"458_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134(2):e175369. https:\/\/doi.org\/10.1172\/jci175369.","journal-title":"J Clin Invest"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","volume":"73","author":"NYL Ngoi","year":"2022","unstructured":"Ngoi NYL, Peng G, Yap TA. A tale of two checkpoints: ATR inhibition and PD-(L)1 blockade. Annu Rev Med. 2022;73:231\u201350. https:\/\/doi.org\/10.1146\/annurev-med-042320-025136.","journal-title":"Annu Rev Med"},{"issue":"9","key":"458_CR7","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti FP, Karukonda P, Clump DA, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T\u00a0cell-dependent antitumor activity following radiation. J Clin Invest. 2018;128(9):3926\u201340. https:\/\/doi.org\/10.1172\/JCI96519.","journal-title":"J Clin Invest"},{"issue":"1","key":"458_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes EE, Walker SM, Taggart LE, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109(1):djw199. https:\/\/doi.org\/10.1093\/jnci\/djw199.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"458_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9.","journal-title":"Nat Commun"},{"issue":"7","key":"458_CR10","first-page":"1307","volume":"8","author":"LL Sun","year":"2018","unstructured":"Sun LL, Yang RY, Li CW, et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T\u00a0cell-mediated killing. Am J Cancer Res. 2018;8(7):1307\u201316.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"458_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng H, Huang Y, Xiao Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. 2020;8(1):e000340. https:\/\/doi.org\/10.1136\/jitc-2019-000340.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"458_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104036","volume":"39","author":"X Feng","year":"2020","unstructured":"Feng X, Tubbs A, Zhang C, et al. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 2020;39(14):EMBJ2019104036. https:\/\/doi.org\/10.15252\/embj.2019104036.","journal-title":"EMBO J"},{"issue":"6","key":"458_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270118","volume":"17","author":"X Jiang","year":"2022","unstructured":"Jiang X, Chen J, Zheng M, Jia H. Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage III NSCLC in China. PLoS ONE. 2022;17(6):e0270118. https:\/\/doi.org\/10.1371\/journal.pone.0270118.","journal-title":"PLoS ONE"},{"issue":"24","key":"458_CR14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"issue":"20","key":"458_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"3","key":"458_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse B, Pons-Tostivint E, Park K, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase\u00a02 umbrella trial. Nat Med. 2024;30(3):716\u201329. https:\/\/doi.org\/10.1038\/s41591-024-02808-y.","journal-title":"Nat Med"},{"issue":"2","key":"458_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim R, Kwon M, An M, et al. Phase\u00a0II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol. 2022;33(2):193\u2013203. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009.","journal-title":"Ann Oncol"},{"issue":"7","key":"458_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041","volume":"10","author":"M Kwon","year":"2022","unstructured":"Kwon M, Kim G, Kim R, et al. Phase\u00a0II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer. 2022;10(7):e005041. https:\/\/doi.org\/10.1136\/jitc-2022-005041.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"458_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/jco.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase\u00a0I trials: the rolling six design. J Clin Oncol. 2008;26(2):190\u20135. https:\/\/doi.org\/10.1200\/jco.2007.12.7712.","journal-title":"J Clin Oncol"},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"viii135","DOI":"10.1093\/annonc\/mdy279.401","volume":"29","author":"M Krebs","year":"2018","unstructured":"Krebs M, Lopez J, El-Khoueiry A, et al. Phase\u00a0I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. Ann Oncol. 2018;29:viii135. https:\/\/doi.org\/10.1093\/annonc\/mdy279.401.","journal-title":"Ann Oncol"},{"key":"458_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4","author":"EL Hardaker","year":"2024","unstructured":"Hardaker EL, Sanseviero E, Karmokar A, et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-45996-4.","journal-title":"Nat Commun"},{"issue":"17","key":"458_CR22","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.Ccr-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer PGS, et al. Phase\u00a0I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res. 2021;27(17):4700\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0251.","journal-title":"Clin Cancer Res"},{"key":"458_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106957","volume":"11","author":"B Besse","year":"2026","unstructured":"Besse B, Felip E, Cho BC, et al. LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): results from LATIFY. ESMO Open. 2026;11:106957. https:\/\/doi.org\/10.1016\/j.esmoop.2026.106957.","journal-title":"ESMO Open"}],"updated-by":[{"DOI":"10.1007\/s40487-026-00461-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000}}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00458-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:07Z","timestamp":1789381927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00458-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00458-3","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised.\nDue to a version control issue introduced during final production stages, several words were inadvertently removed by the publisher from the accepted manuscript and have now been re-instated. Full information regarding the changes made can be found in the Publisher Correction.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40487-026-00461-8","URL":"https:\/\/doi.org\/10.1007\/s40487-026-00461-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Huiwen Sun, Graeme Parr, Edit Lukacs, Daniel Slade, Yizhao Zhou, Xiaoyu Ren, David Kirk, Aleksandra Kmieciak, and Tingting Yao are employees of AstraZeneca. Edit\u00a0Lukacs and Aleksandra Kmieciak also own stock in AstraZeneca. Yuping Sun, Jia Zhong, and Jie Wang have no disclosures.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and patient informed consent form were approved by the institutional review board or independent ethics committee at each study site. The study was performed in accordance with the principles outlined in the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice guidelines, and applicable regulatory authorities. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethics\/Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}